Translational Tumor Immunology Group, Department of Fundamental Oncology, Lausanne, Switzerland.
Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
J Immunother Cancer. 2018 Jul 13;6(1):71. doi: 10.1186/s40425-018-0385-z.
Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not been fully assessed. Here, we demonstrate that CART cells progressively upregulate Fas, FasL, DR5 and TRAIL, which result in their programmed cell death, independently of antigen-mediated TCR or CAR activation. CART cell apoptosis occurs even when the CAR contains a single (co-)activatory domain such as CD3ζ, CD28 or 4-1BB. Importantly, the dominant role of the Fas and DR5 pathways in CART cell apoptosis is demonstrated by the significant rescue of CART cells upon in vivo blockade by combined Fas-Fc and DR5-Fc recombinant proteins. These observations are of crucial importance for the long-term persistence of CART cells and for the development of new applications including the combined TCR and CAR activation against solid tumors.
嵌合抗原受体(CAR)修饰的 T 细胞过继转移已获得 FDA 批准,用于治疗 B 细胞恶性肿瘤。然而,CAR T 细胞中内源性 TCR 的功能尚未得到充分评估。在这里,我们证明 CART 细胞逐渐上调 Fas、FasL、DR5 和 TRAIL,导致其程序性细胞死亡,而与抗原介导的 TCR 或 CAR 激活无关。即使 CAR 包含单个(共)激活结构域,如 CD3ζ、CD28 或 4-1BB,CART 细胞也会发生凋亡。重要的是,通过体内联合 Fas-Fc 和 DR5-Fc 重组蛋白阻断,显著挽救了 CART 细胞,证明了 Fas 和 DR5 途径在 CART 细胞凋亡中的主导作用。这些观察结果对于 CART 细胞的长期持久性以及新应用的开发至关重要,包括针对实体瘤的 TCR 和 CAR 联合激活。